Could a One-Week radiation blast beat three weeks for breast cancer?
NCT ID NCT06559540
First seen Jan 11, 2026
Summary
This phase 2 trial compares a new ultra-short radiation schedule (5 sessions over 1 week) to the current standard (15-16 sessions over 3 weeks) for women with node-positive breast cancer. The goal is to see if the shorter course is just as effective at controlling cancer while causing fewer long-term side effects like arm swelling or heart damage. About 220 participants who have had surgery will be randomly assigned to one of the two radiation plans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NODE POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy
What this could lead to
If successful, this could offer a shorter, more convenient radiation schedule for node-positive breast cancer patients with fewer serious side effects.
What could go wrong
This is a phase 2 trial with only 220 participants, so results are preliminary. The ultra-short schedule may cause unexpected toxicity in the lymph node area.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.